Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ERBB2 Gene Amplification Clear all
Completed Phase 1 Interventional

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518
View directory record Official record
Conditions
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
Interventions
PRT2527
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

NCT01774851
View directory record Official record
Conditions
HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Interventions
MM-111, Paclitaxel, Trastuzumab
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional Results available

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

NCT04209465
View directory record Official record
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational

Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections

NCT01066507
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Applied Spectral Imaging Ltd.
Industry
Eligibility
21 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Lakewood, New Jersey • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2010 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

NCT04439110
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Trastuzumab Emtansine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

NCT00748709
View directory record Official record
Conditions
Neoplasms
Interventions
BIBW 2992 (Afatinib)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

NCT01304784
View directory record Official record
Conditions
HER-2 Gene Amplification
Interventions
Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 3 Interventional

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
89
States / cities
Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 1 Interventional

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

NCT00479856
View directory record Official record
Conditions
Relapsed Breast Cancer, Neoplasms, Breast
Interventions
Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 23, 2026, 6:24 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

NCT06136897
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

NCT01828021
View directory record Official record
Conditions
Breast Cancer
Interventions
Margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 23, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions
A166
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jul 23, 2026, 6:24 AM EDT
Completed No phase listed Observational

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

NCT05902494
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Not listed
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 23, 2026, 6:24 AM EDT